Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Phase IIA Study of the Effect of Flutamide (125 MG/DAY) Taken for 6 Weeks on Expression of Potential Biomarkers of Flutamide Action in the Ovaries of Women at Increased Risk for Ovarian Cancer

NCT00699907 is registered in ClinicalTrials.gov with University of Arizona as lead sponsor.

NCT NCT00699907
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00699907 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Phase IIA Study of the Effect of Flutamide (125 MG/DAY) Taken for 6 Weeks on Expression of Potential Biomarkers of Flutamide Action in the Ovaries of Women at Increased Risk for Ovarian Cancer
Lead sponsor
University of Arizona
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2005
Completion date
November 30, 2014
Enrollment
127 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer